Article
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
Rating:
0.0
Views:
65
Likes:
1
Library:
1
Foghorn Therapeutics Inc.'s stock slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partial hold on a...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value